This is a project that focuses on the development of a dental caries vaccine in humans, based on secretory IgA immune responses to glucosyltransferase from Streptococcus mutans using discrete, but integrated strategies. Project (I) will investigate the nature of T cell defects in resulting secretory IgA responses and will provide means for overcoming these defects. Studies will concentrate on GTF as a thymus dependent antigen of particular importance in dental caries. Methodology using isolated T cells and cloned antigen specific T cells will be used to study the best method(s) to reconstitute SIgA responses. The origin and nature of regulatory T cells required for IgA immune response to GTF will be studied. The subsets of these cells will be characterized as will the presence or absence of Fc alpha receptors using flow fluorocytometry. The GTF specific T cell involved in protective IgA response will be selected by panning, cloned and adoptively transferred into congenitally athymic recipients to test effects on dental caries. The goal of Project (II) is to develop an effective GTF dental caries vaccine. The labial minor salivary glands (MG) will be the source of immunization. Various doses of GTF will be topically applied to MG and the salivary IgA immune response will be tested. The existence and duration of an anamnestic response will be examined. The use of adjuvant to particularize GTF will also be tested as opposed to the immune response to soluble GTF. Further studies will utilize combined oral and topical routes of immunization to optimize immune response to GTF. The effect of this antibody on indigenous S. mutans will be assessed. The integration of these projects will provide an understanding of the regulatory mechanisms of secretory immunity and should allow a knowledgeable manipulation of the human host response to the important antigenic epitopes of GTF, so as to interfere with infection and disease caused by this oral pathogenic microorganism.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
2R01DE004733-09
Application #
3219128
Study Section
Oral Biology and Medicine Study Section (OBM)
Project Start
1977-07-01
Project End
1990-11-30
Budget Start
1986-12-01
Budget End
1987-11-30
Support Year
9
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Forsyth Institute
Department
Type
DUNS #
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Han, Xiaozhe; LaRosa, Karen B; Kawai, Toshihisa et al. (2014) DNA-based adaptive immunity protect host from infection-associated periodontal bone resorption via recognition of Porphyromonas gingivalis virulence component. Vaccine 32:297-303
Smith, Daniel J (2010) Dental caries vaccines: prospects and concerns. Expert Rev Vaccines 9:1-3
Nogueira, R D; King, W F; Gunda, G et al. (2008) Mutans streptococcal infection induces salivary antibody to virulence proteins and associated functional domains. Infect Immun 76:3606-13
Culshaw, S; Larosa, K; Tolani, H et al. (2007) Immunogenic and protective potential of mutans streptococcal glucosyltransferase peptide constructs selected by major histocompatibility complex class II allele binding. Infect Immun 75:915-23
Smith, Daniel J; King, William F; Rivero, Joy et al. (2005) Immunological and protective effects of diepitopic subunit dental caries vaccines. Infect Immun 73:2797-804
Russell, Michael W; Childers, Noel K; Michalek, Suzanne M et al. (2004) A Caries Vaccine? The state of the science of immunization against dental caries. Caries Res 38:230-5
Smith, D J; Lam, A; Barnes, L A et al. (2003) Remote glucosyltransferase-microparticle vaccine delivery induces protective immunity in the oral cavity. Oral Microbiol Immunol 18:240-8
Smith, Daniel J (2003) Caries vaccines for the twenty-first century. J Dent Educ 67:1130-9
Smith, D J (2002) Dental caries vaccines: prospects and concerns. Crit Rev Oral Biol Med 13:335-49
Eastcott, J W; Holmberg, C J; Dewhirst, F E et al. (2001) Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 19:1636-42

Showing the most recent 10 out of 18 publications